The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Health-related quality of life (HRQoL) in advanced endometrial cancer (aEC) patients (pts) treated with lenvatinib plus pembrolizumab or treatment of physician’s choice (TPC).
 
Domenica Lorusso
Honoraria - Amgen; AstraZeneca; Clovis Oncology; GlaxoSmithKline; Merck Serono; MSD
Consulting or Advisory Role - PharmaMar
Speakers' Bureau - AstraZeneca; Clovis Oncology; GlaxoSmithKline; MSD
Research Funding - Clovis Oncology (Inst); GlaxoSmithKline (Inst); MSD (Inst); PharmaMar (Inst)
Travel, Accommodations, Expenses - AstraZeneca; Clovis Oncology; GlaxoSmithKline; GlaxoSmithKline; PharmaMar; Roche
 
Nicoletta Colombo
Honoraria - Amgen; AstraZeneca; Clovis Oncology; Eisai; GlaxoSmithKline; Immunogen; mersana; mersana; MSD Oncology; Novartis; Pfizer; Pfizer; PharmaMar; Roche/Genentech; Tesaro
Consulting or Advisory Role - AstraZeneca; BioCad; Clovis Oncology; Eisai; GlaxoSmithKline; Immunogen; mersana; MSD Oncology; Pfizer; Pfizer; PharmaMar; Roche/Genentech; Tesaro
 
Antonio Casado Herraez
Honoraria - AstraZeneca; Eisai; Lilly; MSD; PharmaMar; Roche; Tesaro
Consulting or Advisory Role - Eisai; MSD
Research Funding - PharmaMar (Inst)
Travel, Accommodations, Expenses - Lilly; PharmaMar; Roche
 
Alessandro Santin
Consulting or Advisory Role - Merck; Tesaro
Research Funding - Boehringer Ingelheim (Inst); Genentech/Roche (Inst); Genentech/Roche (Inst); Gilead Sciences (Inst); Immunomedics (Inst); Merck (Inst); Puma Biotechnology (Inst); R-Pharm (Inst); Tesaro (Inst)
 
Emeline Colomba
Honoraria - Bristol-Myers Squibb; GlaxoSmithKline; Ipsen; Merck
Travel, Accommodations, Expenses - Bristol-Myers Squibb; Ipsen; Pfizer
 
David Scott Miller
Consulting or Advisory Role - Abbvie; Alexion Pharmaceuticals; Alexion Pharmaceuticals; AstraZeneca; Asymmetric Therapeutics; BOSTON BIOMEDICAL RESEARCH INSTITUTE; Clovis Oncology; Eisai; Genentech; GlaxoSmithKline; Guardant Health; Guardant Health; Incyte; Janssen; Janssen Oncology; Karyopharm Therapeutics; Merck Sharp & Dohme (Inst); Myriad Genetic Laboratories; Tarveda Therapeutics; Tesaro
Speakers' Bureau - Clovis Oncology; Genentech
Research Funding - Advaxis (Inst); Advenchen Laboratories (Inst); Aeterna Zentaris (Inst); Agenus (Inst); Akeso Biopharma (Inst); Aprea AB (Inst); AstraZeneca (Inst); Immunogen (Inst); Janssen (Inst); Karyopharm Therapeutics (Inst); Leap Therapeutics (Inst); Mateon Therapeutics (Inst); Merck Sharp & Dohme (Inst); Millenium Pharamceuticals (Inst); Novartis (Inst); NVision (Inst); Pfizer (Inst); Regeneron (Inst); Syros Pharmaceuticals (Inst); Tesaro (Inst); TRACON Pharma (Inst); US Biotest (Inst); Xenetic Biosciences (Inst)
 
Keiichi Fujiwara
Honoraria - Chugai Pharma; Daiichi Sankyo; Eisai; Kyowa Hakko Kirin; Nippon Kayaku; Ono Pharmaceutical; Taiho Pharmaceutical; Takeda; Zeria Pharmaceutical
Consulting or Advisory Role - Abbvie; AstraZeneca; Eisai; Genmab; MSD; Pfizer; Taiho Pharmaceutical; Takeda
Research Funding - AstraZeneca (Inst); Chugai Pharma (Inst); Eisai (Inst); Genmab (Inst); Immunogen (Inst); Kaken Pharmaceutical (Inst); Lilly (Inst); MSD (Inst); Oncotherapeutics (Inst); Ono Pharmaceutical (Inst); Regeneron (Inst); Shionogi (Inst); Zeria Pharmaceutical (Inst)
Travel, Accommodations, Expenses - Abbvie; MSD; Pfizer
 
Sandro Pignata
Honoraria - AstraZeneca; MSD; pfizer; pharmamar; Roche; Tesaro
Consulting or Advisory Role - AstraZeneca; Clovis Oncology; Pfizer; PharmaMar; Roche; tesaro
Research Funding - AstraZeneca (Inst); MSD (Inst); Pfizer (Inst); Roche (Inst)
 
Sally E. Baron-Hay
Consulting or Advisory Role - AstraZeneca; Merck Sharpe and Doehme; Novartis
 
Isabelle Laure Ray-Coquard
Honoraria - Abbvie; Advaxis; Amgen; AstraZeneca; Bristol-Myers Squibb; Clovis Oncology; DECIPHERA; Genmab; GlaxoSmithKline; MERSANA; MSD Oncology; OxOnc; Pfizer; PharmaMar; Roche; Tesaro
Consulting or Advisory Role - Abbvie; AstraZeneca; Bristol-Myers Squibb; Clovis Oncology; Deciphera; Genmab; GlaxoSmithKline; Mersana; Mersana; MSD Oncology; Pfizer; PharmaMar; Roche; Tesaro
Research Funding - BMS; MSD Oncology
Travel, Accommodations, Expenses - Advaxis; AstraZeneca; BMS; Clovis Oncology; Clovis Oncology; GlaxoSmithKline; PharmaMar; Roche; Tesaro
(OPTIONAL) Uncompensated Relationships - Arcagy-Gineco; French National Cancer Institute (INCA)
 
Ronnie Shapira-Frommer
Honoraria - AstraZeneca; Bristol-Myers Squibb; Medison; MSD; NeoPharm; Novartis; Roche
Consulting or Advisory Role - MSD; VBL Therapeutics
Research Funding - MSD
 
Yong Man Kim
Stock and Other Ownership Interests - Genolution; Johnson & Johnson
Research Funding - Regeneron; Roche
 
Mary McCormack
Research Funding - Roche/Genentech (Inst)
Travel, Accommodations, Expenses - Roche
 
Steven Bird
Employment - Merck
Stock and Other Ownership Interests - Merck
 
Vimalanand S. Prabhu
Employment - Merck; Merck (I)
Stock and Other Ownership Interests - Merck
Travel, Accommodations, Expenses - Merck
 
Allison Martin Nguyen
Employment - Merck
Stock and Other Ownership Interests - Merck
 
Qi Zhao
Employment - Eisai
 
Lea Dutta
Employment - Eisai
Research Funding - Eisai
 
Vicky Makker
Honoraria - Eisai; IBM; Karyopharm Therapeutics; Merck
Consulting or Advisory Role - ArQule; Clovis Oncology; Eisai; Faeth Therapeutics; GlaxoSmithKline; IBM; Karyopharm Therapeutics; Merck; Takeda
Research Funding - AstraZeneca (Inst); Bayer (Inst); Bristol-Myers Squibb (Inst); Clovis Oncology (Inst); Eisai (Inst); Karyopharm Therapeutics (Inst); Lilly (Inst); Merck (Inst); Takeda (Inst); Zymeworks (Inst)
Travel, Accommodations, Expenses - Eisai; Karyopharm Therapeutics; Merck
Other Relationship - IBM